.jpg)
OpenAI announced today the acquisition of Orchestra Bio, an AI firm specializing in biotechnology development. The value of the deal was not disclosed. This acquisition is expected to further strengthen OpenAI’s position and development efforts within the biotechnology sector.
Orchestra Bio provides AI agents designed to assist biotechnology companies in managing operations related to medical development and research—including support for financial management, scheduling, and other operational tasks.
OpenAI is expected to integrate this team with its existing life sciences division. As technology evolves, a number of artificial intelligence companies are now expanding their offerings beyond traditional software, venturing into fields such as science and mathematics.
